H.R. 6577 · 115th Congress
Price Relief, Innovation, and Competition for Essential Drugs Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SchakowskySponsorNo cosponsors.
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
What it does: CRS summary · Introduced in House · Jul 26, 2018
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.
This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Price Relief, Innovation, and Competition for Essential Drugs Act
Also known as: PRICED Act
Latest action (Jul 27, 2018): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jul 26, 2018
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.